(19)
(11) EP 4 514 856 A2

(12)

(43) Date of publication:
05.03.2025 Bulletin 2025/10

(21) Application number: 23797108.0

(22) Date of filing: 25.04.2023
(51) International Patent Classification (IPC): 
C07K 16/30(2006.01)
 A61K 39/395(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2803; C07K 2317/21; A61K 39/39591; C07K 2317/94
(86) International application number:
PCT/US2023/019713
(87) International publication number:
WO 2023/211873 (02.11.2023 Gazette 2023/44)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 29.04.2022 US 202263336670 P

(71) Applicant: Merck Sharp & Dohme LLC
Rahway, New Jersey 07065 (US)

(72) Inventors:
  • ANTOCHSHUK, Valentyn
    South San Francisco, California 94080 (US)
  • DESAI, Preeti G.
    Westfield, New Jersey 07090 (US)

(74) Representative: Merck Sharp & Dohme LLC 
120 Moorgate
London EC2M 6UR
London EC2M 6UR (GB)

   


(54) PHARMACEUTICAL FORMULATIONS OF AN ANTI-ILT4 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREROF AND METHODS OF USE